Systemic Sclerosis Clinical Trial
— ESSE2016Official title:
Effects of an Individualized, Home-based Exercise Program for the Patient With Systemic Sclerosis, on Exercise Capacity, Hand Mobility and Quality of Life: a Randomized, Controlled Study.
NCT number | NCT03614208 |
Other study ID # | ESSE2016 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | February 1, 2017 |
Est. completion date | March 1, 2018 |
Verified date | August 2018 |
Source | Universita di Verona |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Systemic sclerosis (SSc) is an uncommon chronic rheumatic disease with an unknown cause and
unpredictable course. The inability, in addition to easy fatigability, starts a vicious
circle that leads to a fast deterioration of physical conditions that cause a reduction of
aerobic exercise capacity and, consequently, of health-related quality of life (HRQoL).
Aerobic exercise has already been shown to be safe and effective in improving exercise
capacity and HRQoL of patients with chronic cardiovascular and pulmonary diseases. However,
few studies have evaluated the role of specific exercise programs on the muscular impairment
in SSc. Nevertheless, the results obtained in preliminary reports are promising, and, for
these reasons, the management of muscular impairment in SSc could include an appropriate
rehabilitation program besides pharmaceutical and surgical treatments.
The primary aim of this study will be to evaluate the effect of an individualized exercise
program performed at home on aerobic capacity evaluated by 6 minutes walking test.
Secondary aims will be to evaluate: 1- VO2max, measured by cardiopulmonary test; 2- the
effect of the same program on the muscular strength of upper and lower limbs; 3- the efficacy
of a self-administered stretching program for finger joint motion. Secondary aims will be
also 1-to ascertain whether a comprehensive exercise program may affect, besides physical
function, HRQoL; 2- and to evaluate the adherence during two periods of three months, one
whit and one without supervision and reinforcement by a phone call.
All the patients with a diagnosis of SSc, according to the criteria of American College of
Rheumatology (ACR), who attended the Rheumatologic outpatient clinic of our institution will
be evaluated in order to participate in the rehabilitation program. The pneumological
examination and two days of screening and testing will take place at the outpatient's clinic
of Respiratory Medicine and Sport of our institution.
Status | Completed |
Enrollment | 33 |
Est. completion date | March 1, 2018 |
Est. primary completion date | March 1, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility |
Inclusion Criteria: - diagnosis of SSc according to the criteria of ACR - no hospitalizations in the previous 3 months - no change in anti-rheumatic treatment in the previous 3 months - signed informed consent Exclusion Criteria: - heart failure staging in classes III or IV of New York Heart Association (NYHA) - pulmonary hypertension, defined by echocardiogram as a right ventricular systolic pressure = 45mmHg - vital capacity (VC) = 50% or diffusion lung capacity of carbon monoxide (DLCO) = 30% of predicted values. - renal failure defined as a calculated glomerular filtration rate (GFR) < 30ml/min, in agreement with the staging of International Federation of National Kidney Foundations - inability to perform the rehabilitation program due to skeletal-muscle impairments or other illnesses - pregnancy or planned pregnancy in the next 6 months - psychiatric disorders that prevent collaboration and adherence at the rehabilitation the program, including drug abuse - involvement in ongoing aerobic or anaerobic exercise programs Drop out criteria: - the demonstration of ischemic heart disease after cardiopulmonary exercise testing performed at baseline - need to change the dosage or interruption of prostanoids used in the treatment of SSc during the 6 months of the treatment |
Country | Name | City | State |
---|---|---|---|
Italy | Azienda Ospedaliera, SSO respiratory pathophysiology Unit, Verona | Verona | Italy/Verona |
Lead Sponsor | Collaborator |
---|---|
Universita di Verona |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Six minute walking test | Evaluate aerobic capacity | Up to six months | |
Secondary | Maximum oxygen consumption (VO2max) | Evaluate the maximum volume of oxygen that a human can consume in the unit of time, measured by cardiopulmonary test | Up to six months | |
Secondary | Handgrip strength | Handgrip strength will be measured in kilograms using a hydraulic hand-held dynamometer (Saehan Corp., Masan, Korea).Will be recorded, for each hand, the best result between three attempts. | Up to six months | |
Secondary | Muscular strength of upper limbs | Biceps strength will be measured in kilograms by an isometric forearm flexion using a dynamometer (Kern CH50K50, Kern&Sohn, Balingen, Germany) perpendicularly fixed on the floor. Will be recorded, for each arm, the best result between three attempts. | Up to six months | |
Secondary | One repetition maximum (1-RM) of biceps strength | One repetition maximum (1-RM) of biceps strength, expressed in kilograms, will be determinated by using the submaximal estimation method (predicted 1-RM) with the formula of Brzycke. | Up to six months | |
Secondary | Muscular strength of lower limbs | Quadriceps strength will be measured in kilograms by an isometric leg extension. The subject will be seated in an adjustable, straight-backed chair with the lower leg unsupported and the hip and knee flexed in a 90° angle, with an adjustable belt around the hips. Isometric leg extension strength will be measured by a dynamometer (Kern CH50K50, Kern & Sohn, Balingen, Germany) applied with a strap around the ankle just proximal to malleoli. Will be recorded, for each lower limb, the best result between three attempts. | Up to six months | |
Secondary | Hand Mobility in Scleroderma test (HAMIS-test) | Evaluate finger joint motion and hand function | Up to six months | |
Secondary | Short Form - 36 (SF-36) | It is a self-reported questionnaire for evaluating the health status. It contains 36 items, measuring quality of life with two summary measures, a physical component score (PCS) and a mental component score (MCS). | Up to six months | |
Secondary | Health assessment questionnaire - disability index (HAQ-DI) | This questionnaire indicates the extent of functional abilities. It consists in 20 items divided into eight categories. For each one of the items the score can range from 0 (lack of disability) to 3 (complete disability). | Up to six months | |
Secondary | Adherence to exercise program, only for treatment group | Evaluate the adherence, using a diary, during two periods of three months, one whit and one without supervision and reinforcement by phone call | Up to six months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03274076 -
Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)
|
Phase 1/Phase 2 | |
Completed |
NCT04300426 -
Safety and Efficacy of Anaerobic Cultivated Human Intestinal Microbiome Transplantation in Systemic Sclerosis (ReSScue)
|
Phase 2 | |
Recruiting |
NCT06058091 -
RY_SW01 Cell Injection Therapy in Systemic Sclerosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT04356755 -
Subcutaneous Injections of ASC to Heal Digital Ulcers in Patients With Scleroderma.
|
Phase 2 | |
Suspended |
NCT06210945 -
Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis
|
Phase 2 | |
Not yet recruiting |
NCT05947682 -
Manufacturing of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells for Treatment of Severe Systemic Sclerosis
|
N/A | |
Not yet recruiting |
NCT04303208 -
Sirtuin 3 and Sirtuin 7 in Systemic Sclerosis
|
N/A | |
Not yet recruiting |
NCT05177380 -
Efficacy of a Personalized Rehabilitation Program of Facial Involvement in Systemic Sclerosis
|
N/A | |
Recruiting |
NCT02551042 -
CSL Behring Sclero XIII
|
Phase 2 | |
Terminated |
NCT02243111 -
Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound
|
N/A | |
Terminated |
NCT02246348 -
Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc)
|
N/A | |
Completed |
NCT01933334 -
Safety and Tolerability of Pirfenidone in Patients With Systemic Sclerosis−Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)
|
Phase 2 | |
Completed |
NCT01468792 -
Hemodynamic Changes in Connective Tissue Disease
|
N/A | |
Terminated |
NCT00848107 -
Open-Label Study of Oral Treprostinil in Digital Ulcers
|
Phase 2 | |
Completed |
NCT00984932 -
Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary Hypertension
|
Phase 3 | |
Completed |
NCT00074568 -
Scleroderma Registry
|
||
Not yet recruiting |
NCT06412614 -
Evaluation of Patients With Systemic Sclerosis Without Specific or Associated Autoantibodies
|
||
Terminated |
NCT00622687 -
Effect of Different Iloprost Doses on Symptoms in Systemic Sclerosis
|
Phase 2 | |
Recruiting |
NCT04464434 -
Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis
|
Phase 4 | |
Recruiting |
NCT04246528 -
SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF)
|
N/A |